专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013038429A2 NOVEL SGLT INHIBITORS 审中-公开
标题翻译：新型SGLT抑制剂
公开(公告)号：WO2013038429A2
公开(公告)日：2013-03-21
申请号：PCT/IN2012/000612
申请日：2012-09-12
申请人： PANACEA BIOTEC LTD. , JAIN, Rajesh , TREHAN, Sanjay , DAS, Jagattaran , NANDA, Gurmeet, Kaur , THUNGATHURTHI, Sastry, V., R., S. , SINGH, Nishan , SHARMA, Sudhir, Kumar
发明人： JAIN, Rajesh , TREHAN, Sanjay , DAS, Jagattaran , NANDA, Gurmeet, Kaur , THUNGATHURTHI, Sastry, V., R., S. , SINGH, Nishan , SHARMA, Sudhir, Kumar
IPC分类号： A61K31/70
CPC分类号： C07D309/10 , C07D493/08 , C07H7/04
摘要： The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula (I) and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
摘要翻译：本发明涉及式（I）的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物。本发明还涉及合成式（I）的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。本发明还提供包含式（I）的新型化合物和治疗或预防可通过抑制葡萄糖转运蛋白-2（SGLT-2）调节或归一化的一种或多种病症或疾病的药物组合物。

2. 发明申请

WO2012172566A2 NOVEL SGLT INHIBITORS 审中-公开
标题翻译：新型SGLT抑制剂
公开(公告)号：WO2012172566A2
公开(公告)日：2012-12-20
申请号：PCT/IN2012000416
申请日：2012-06-13
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , TREHAN SANJAY , DAS JAGATTARAN , NANDA GURMEET KAUR , THUNGATHURTHI SASTRY V R S , SINGH NISHAN , SHARMA SUDHIR KUMAR
发明人： JAIN RAJESH , TREHAN SANJAY , DAS JAGATTARAN , NANDA GURMEET KAUR , THUNGATHURTHI SASTRY V R S , SINGH NISHAN , SHARMA SUDHIR KUMAR
IPC分类号： C07H15/203
CPC分类号： A61K31/7048 , A61K31/70 , C07D309/10 , C07D401/04 , C07D493/08 , C07H7/04 , C07H9/04 , C07H13/04 , C07H13/12 , C07H15/04 , C07H19/01
摘要： The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula (I) and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
摘要翻译：本发明涉及式（I）的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物。本发明还涉及合成式（I）的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。本发明还提供包含式（I）的新型化合物和治疗或预防可通过抑制葡萄糖转运蛋白-2（SGLT-2）调节或归一化的一种或多种病症或疾病的药物组合物。

3. 发明申请

WO2012085936A3 RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS PLASMIDS AND VACCINES 审中-公开
标题翻译：重组呼吸道合胞病毒质粒和疫苗
公开(公告)号：WO2012085936A3
公开(公告)日：2012-10-11
申请号：PCT/IN2011000871
申请日：2011-12-19
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , VINAYAK VIRENDER KUMAR , AGGARWAL NEERAJ , JAISWAL PALLAVI
发明人： JAIN RAJESH , VINAYAK VIRENDER KUMAR , AGGARWAL NEERAJ , JAISWAL PALLAVI
IPC分类号： A61K39/155 , C07K14/115 , C12N15/863
CPC分类号： A61K39/155 , A61K39/12 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2710/24143 , C12N2760/18522 , C12N2760/18534
摘要： The present invention relates to novel recombinant plasmids comprising a cassette of at least one, or at least two, or at least three or most preferably at least four foreign genes from Respiratory syncytial virus (RSV) wherein the said genes are inserted at a non-essential site preferably Del III, within the modified vaccinia Ankara (MVA) genome. The invention further relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneous expression of a cassette comprising of at least one, or at least two, or at least three or most preferably at least four foreign genes from Respiratory syncytial virus (RSV), wherein the said genes are inserted at a non-essential site preferably Del III, within the modified vaccinia Ankara (MVA) genome. The invention further provides compositions and method of treatment using the novel recombinant virus.
摘要翻译：本发明涉及新的重组质粒，其包含来自呼吸道合胞病毒（RSV）的至少一个，或至少两个，或至少三个，或最优选至少四个外源基因的盒，其中所述基因以非人免疫球蛋白在改良的安卡拉痘苗病毒（MVA）基因组内，必需位点优选Del III。本发明还涉及包含并能够同时表达包含来自呼吸道合胞病毒的至少一个，或至少两个，或至少三个或最优选至少四个外源基因的盒的重组改良的安卡拉痘苗病毒（MVA）病毒（RSV），其中所述基因插入修饰的牛痘Ankara（MVA）基因组内的非必需位点，优选Del III。本发明进一步提供了使用该新型重组病毒的组合物和治疗方法。

4. 发明申请

WO2012098562A2 LIQUID ORAL COMPOSITIONS OF LANTHANUM SALTS 审中-公开
标题翻译：液体口服组合物
公开(公告)号：WO2012098562A2
公开(公告)日：2012-07-26
申请号：PCT/IN2012/000041
申请日：2012-01-17
申请人： PANACEA BIOTEC LIMITED , JAIN, Rajesh , SINGH, Sarabjit , SINGH, Paramjit , SINGH, Pirthi Pal
发明人： JAIN, Rajesh , SINGH, Sarabjit , SINGH, Paramjit , SINGH, Pirthi Pal
IPC分类号： A61K33/24 , A61K47/02 , A61K47/14 , A61K47/26 , A61K47/38 , A61K9/00
CPC分类号： A61K9/0053 , A61K9/0095 , A61K33/24 , A61K47/02 , A61K47/14 , A61K47/26 , A61K47/38
摘要： The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.
摘要翻译：本发明涉及镧的液体口服药物组合物及其药学上可接受的盐。本发明还涉及镧及其盐的液体口服药物组合物的制备，并且还提供了这些组合物在患者中治疗高磷血症的用途。

5. 发明申请

WO2012085936A2 RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS PLASMIDS AND VACCINES 审中-公开
标题翻译：重组呼吸道同源病毒和疫苗
公开(公告)号：WO2012085936A2
公开(公告)日：2012-06-28
申请号：PCT/IN2011/000871
申请日：2011-12-19
申请人： PANACEA BIOTECH LTD , JAIN, Rajesh , VINAYAK, Virender, Kumar , AGGARWAL, Neeraj , JAISWAL, Pallavi
发明人： JAIN, Rajesh , VINAYAK, Virender, Kumar , AGGARWAL, Neeraj , JAISWAL, Pallavi
IPC分类号： C12N7/00
CPC分类号： A61K39/155 , A61K39/12 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2710/24143 , C12N2760/18522 , C12N2760/18534
摘要： The present invention relates to novel recombinant plasmids comprising a cassette of at least one, or at least two, or at least three or most preferably at least four foreign genes from Respiratory syncytial virus (RSV) wherein the said genes are inserted at a non-essential site preferably Del III, within the modified vaccinia Ankara (MVA) genome. The invention further relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneous expression of a cassette comprising of at least one, or at least two, or at least three or most preferably at least four foreign genes from Respiratory syncytial virus (RSV), wherein the said genes are inserted at a non-essential site preferably Del III, within the modified vaccinia Ankara (MVA) genome. The invention further provides compositions and method of treatment using the novel recombinant virus.
摘要翻译：本发明涉及包含呼吸道合胞病毒（RSV）的至少一种，或至少两种，或至少三种或最优选至少四种外来基因的盒的新型重组质粒，其中所述基因以非 - 必需部位，优选Del III，在修饰的痘苗安卡拉（MVA）基因组内。本发明还涉及重组修饰的痘苗安卡拉（MVA）病毒，其包含并能够同时表达包含呼吸道合胞体病毒中至少一种，或至少两种，或至少三种，或最优选至少四种外来基因的盒（RSV），其中所述基因插入在修饰的痘苗安卡拉（MVA）基因组内的非必需位点，优选地为Del III。本发明还提供了使用该新型重组病毒的组合物和治疗方法。

6. 发明申请

WO2012035559A3 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN 审中-公开
标题翻译：包含PREGABALIN的持续释放药物组合物
公开(公告)号：WO2012035559A3
公开(公告)日：2012-06-28
申请号：PCT/IN2011000638
申请日：2011-09-15
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , SINGH SARABJIT , PUTHLI SHIVANAND
发明人： JAIN RAJESH , SINGH SARABJIT , PUTHLI SHIVANAND
IPC分类号： A01N37/12 , A61K31/195
CPC分类号： A61K9/0002 , A61K9/1623 , A61K9/2018 , A61K9/2054 , A61K31/197 , A61K47/26
摘要： The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.
摘要翻译：本发明涉及稳定的每日缓释药物组合物，其包含普瑞巴林或其药学上可接受的盐和药学上可接受的赋形剂，其中药物组合物与普瑞巴林的常规速释制剂每天施用两次是生物等效的。本发明进一步涉及包含普瑞巴林和糖酯作为用于维持药物的均匀释放速率的释放延缓剂的组合物以及制备这种口服缓释制剂的方法。

7. 发明申请

WO2012077138A1 METHODS OF CRYSTALLIZING (R) -1- (3 -HYDROXYPROPYL) -5- [2- [2- [2- ( 2, 2, 2 - TRIFLUOROETHOXY) PHENOXY] ETHYLAMINO] PROPYL] INDOLINE-7 -CARBOXAMIDE 审中-公开
标题翻译：（R）-1-（3-羟基丙基）-5- [2- [2- [2-（2,2,2-三氟甲基）苯氧基]乙酰胺]丙基]吲哚-7-羧酰胺的方法
公开(公告)号：WO2012077138A1
公开(公告)日：2012-06-14
申请号：PCT/IN2011/000842
申请日：2011-12-08
申请人： PANACEA BIOTEC LIMITED , JAIN, Rajesh , SIRIPRAGADA, Mahender, Rao , RAO, Jagadeeshwar, R
发明人： JAIN, Rajesh , SIRIPRAGADA, Mahender, Rao , RAO, Jagadeeshwar, R
IPC分类号： C07D209/08 , B01D9/02
CPC分类号： C07D209/08 , B01D9/0054
摘要： The present invention provides a process for crystallization of various forms of silodosin. In particular the present invention provides a process for crystallizing α and β forms of silodosin from various solvents and their mixtures using various crystallization techniques.
摘要翻译：本发明提供了各种形式的西洛德辛结晶的方法。特别地，本发明提供了一种使用各种结晶技术从各种溶剂及其混合物中结晶和形成silodosin的方法。

8. 发明申请

WO2012053006A3 IMPROVED ORAL FAST DISSOLVING FILMS COMPRISING COMBINATION OF POLYMERS AND METHOD OF PREPARATION THEREOF 审中-公开
公开(公告)号：WO2012053006A3
公开(公告)日：2012-04-26
申请号：PCT/IN2011/000715
申请日：2011-10-17
申请人： PANACEA BIOTEC LTD , JAIN, Rajesh , SINGH, Sarabjit , SINGH, Paramjit , SAILDESAI, Mansi
发明人： JAIN, Rajesh , SINGH, Sarabjit , SINGH, Paramjit , SAILDESAI, Mansi
IPC分类号： A61K9/70 , A61K9/00
摘要： The invention relates to an oral film having reduced adherence to oral cavity comprising water-soluble polymer as an essential polymer base in combination with film former, wherein the ratio of water-soluble polymer to the film former is about 25: 1 to about 250: 1 that is suitable for delivering drugs from various pharmacological categories ranging from conventional small molecules to proteins or peptides. In particular the invention relates to oral films which are bioequivalent to conventional immediate release oral dosage forms and exhibiting one or more favorable properties such as fast dissolution time, improved drug loading, improved mechanical properties (burst strength, tensile strength, modules of elongation).

9. 发明申请

WO2011101864A1 NOVEL PROCESS FOR THE SYNTHESIS OF PHENOXYETHYL DERIVATIVES 审中-公开
标题翻译：用于合成苯乙烯衍生物的新方法
公开(公告)号：WO2011101864A1
公开(公告)日：2011-08-25
申请号：PCT/IN2011/000093
申请日：2011-02-14
申请人： PANACEA BIOTEC LTD , JAIN, Rajesh , JAGDEESHWAR, Rao R. , MAHENDER, Rao Siripragada
发明人： JAIN, Rajesh , JAGDEESHWAR, Rao R. , MAHENDER, Rao Siripragada
IPC分类号： C07D209/08 , C07C43/23
CPC分类号： C07D209/08 , C07C41/16 , C07C41/26 , C07C303/28 , C07C43/225 , C07C43/23 , C07C309/66
摘要： The present invention provides an improved process for the synthesis of 2-[2- (2,2,2-trifluoroethoxy)phenoxy]ethanol intermediate, its derivatives and/or its pharmaceutically acceptable salts, useful in the synthesis of α-1 adrenoceptor blockers such as silodosin.
摘要翻译：本发明提供了用于合成α-1肾上腺素受体阻断剂的2- [2-（2,2,2-三氟乙氧基）苯氧基]乙醇中间体及其衍生物和/或其药学上可接受的盐的合成方法。如silodosin。

10. 发明申请

WO2011070592A2 NOVEL SUGAR DERIVATIVES 审中-公开
标题翻译：新糖衍生物
公开(公告)号：WO2011070592A2
公开(公告)日：2011-06-16
申请号：PCT/IN2010000796
申请日：2010-12-09
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , TREHAN SANJAY , THUNGATHURTHI SASTRY V R S , NANDA GURMEET KAUR , DAS JAGATTARAN , MAGADI SITARAM KUMAR , SHARMA SUDHIR KUMAR
发明人： JAIN RAJESH , TREHAN SANJAY , THUNGATHURTHI SASTRY V R S , NANDA GURMEET KAUR , DAS JAGATTARAN , MAGADI SITARAM KUMAR , SHARMA SUDHIR KUMAR
CPC分类号： C07H15/04 , C07D309/10
摘要： The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2). The invention also relates to the use of compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof, for the manufacture of a medicament for the prophylaxis, amelioration and/or treatment of conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2) and the related diseases, disorders and conditions, in a subject in need thereof.
摘要翻译：本发明涉及式（I）的新化合物，其药学上可接受的衍生物，类似物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物。本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，类似物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。本发明还提供包含式I的新化合物和治疗或预防一种或多种可通过抑制葡萄糖转运蛋白-2（SGLT-2）调节或归一化的病症或疾病的药物组合物。本发明还涉及式I化合物，其药学上可接受的衍生物，类似物，互变异构体形式，异构体，多晶型物，前体药物，代谢物，盐或溶剂合物在制备用于预防和/或改善在有需要的受试者中通过抑制葡萄糖转运蛋白-2（SGLT-2）和相关疾病，病症和病症来调节或归一化的病症或疾病的治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式